Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after 24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.


Options:
A: Arm Label: BI 10773 low (drug naive); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: BI 10773 high (drug naive); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: Placebo (drug naive); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sitagliptin 100mg (drug naive); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Sitagliptin 100mg | Arm Label: BI 10773 low (pioglitazone); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: BI 10773 high (pioglitazone); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo (pioglitazone); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BI 10773 low (metformin); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: BI 10773 high (metformin); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo (metformin); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BI 10773 low (metformin+sulfonylurea); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: BI 10773 high (metformin+sulfonylurea); Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo (metformin+sulfonylurea); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sitagliptin 100mg (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sitagliptin 100mg (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (metformin) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low (metformin+sulfonylurea) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (drug naive) | Intervention Type: DRUG; Name: Sitagliptin 100mg; Assigned to Arm(s): Sitagliptin 100mg (drug naive) | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (pioglitazone) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (drug naive) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high (metformin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (metformin+sulfonylurea) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low (drug naive)
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glibenclamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: glibenclamide, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: glibenclamide; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide
C: Intervention Type: DRUG; Name: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 2

Answer: B